BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/3/2019 7:56:59 AM | Browse: 866 | Download: 1027
 |
Received |
|
2019-06-27 00:24 |
|
Peer-Review Started |
|
2019-06-29 04:07 |
|
To Make the First Decision |
|
2019-08-02 07:03 |
|
Return for Revision |
|
2019-08-02 09:08 |
|
Revised |
|
2019-08-07 14:42 |
|
Second Decision |
|
2019-08-16 12:47 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-08-20 03:05 |
|
Articles in Press |
|
2019-08-20 03:05 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-08-27 07:38 |
|
Publish the Manuscript Online |
|
2019-09-03 07:56 |
| ISSN |
2308-3840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Review |
| Article Title |
Antidiabetic agents in patients with hepatic impairment
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Athanasia Papazafeiropoulou and Αndreas Μelidonis |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Athanasia Papazafeiropoulou, MD, MSc, PhD, Attending Doctor, Research Scientist, 1st Department of Internal Medicine and Diabetes Center, Tzaneio General Hospital of Piraeus, 1 Zanni and Afentouli Street, Athens 18536, Greece. pathan@ath.forthnet.gr |
| Key Words |
Hepatic impairment; Type 2 diabetes mellitus; Pharmacokinetics; Antidiabetic drugs; ; |
| Core Tip |
Most of the antidiabetic agents, with the exception of insulin, need dosage titration due to alterations to their pharmacokinetics in patients with chronic liver disease (CLD). For well-established antidiabetic treatments, like metformin and sulfonylureas there are studies regarding their dosage chance in these patients. However, despite the growing problem of management of diabetes in patients with CLD the existing literature data, especially on newer antidiabetic agents, are limited and, furthermore, no direct guidelines exist. Therefore, in the present review article we try to summarize the existing literature data regarding management of diabetes in patients with CLD. |
| Publish Date |
2019-09-03 07:56 |
| Citation |
Pazafiropoulou A, Melidonis A. Antidiabetic agents in patients with hepatic impairment. World J Meta-Anal 2019; 7(8): 380-388 |
| URL |
https://www.wjgnet.com/2308-3840/full/v7/i8/380.htm |
| DOI |
https://dx.doi.org/10.13105/wjma.v7.i8.380 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
